Related Experiment Video
Updated: Sep 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment
Muhammad Tayyab Azam1, Muhammad Hussain Azam1, Muhammad Arif Khan1
1Dow Medical College, Dow University of Health and Sciences, Karachi, Pakistan.
Background:
Two-drug antiretroviral regimens are increasingly explored to simplify HIV-1 treatment while maintaining durable viral suppression. Doravirine combined with Islatravir (DOR/ISL) represents a novel non-integrase strand transfer inhibitor (non-INSTI) regimen. However, comprehensive synthesized evidence remains limited.
Objectives:
To systematically evaluate the efficacy and safety of fixed-dose Doravirine (100 mg) plus Islatravir (0.25 or 0.75 mg) for HIV-1 treatment in adults.
Design:
Systematic Review and Meta-Analysis.
Data Sources And Methods:
Comprehensive searches of PubMed, Embase, Scopus, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify RCTs evaluating Doravirine/Islatravir for HIV-1 treatment. The primary outcome was viral suppression (HIV-1 RNA <50 copies/mL) at 48 weeks. Secondary outcomes included immunological and safety endpoints.
Results:
Seven RCTs (N = 3,589) were included. In primary analyses restricted to the approved 0.25 mg dose (four RCTs, N = 1,639), DOR/0.25 mg ISL achieved non-inferior viral suppression compared to standard ART at 48 weeks (RR = 1.01, 95% CI: 0.97-1.04, p = 0.63), with consistent efficacy across virologically suppressed and treatment-naïve cohorts. DOR/0.25 mg ISL showed no significant differences versus controls in CD4+ cell count (MD = -6.35 cells/µL, p = 0.51) or total lymphocyte count changes (MD = -0.02 x 109/L, p = 0.54). Statistically significant declines in CD4+ and lymphocyte counts were strictly restricted to the discontinued 0.75 mg dose. Overall adverse events and treatment discontinuations due to adverse events were comparable between groups.
Conclusion:
DOR/ISL provides non-inferior virologic efficacy compared with standard antiretroviral therapy with a favorable safety profile. The 0.25 mg Islatravir dose maintains antiviral efficacy while avoiding the immunologic declines observed with 0.75 mg dose, supporting its suitability as a simplified two-drug regimen.
Registration:
This review protocol was prospectively registered with PROSPERO (CRD420261321479).
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Overview and Classification
Inhibitors of Virion Maturation and Assembly
Antiprotozoal Agents
Dosage Regimens: Designs and Approaches

